Cetrorelix Adverse Events: What the Label and Studies Report

What Cetrorelix Is, at Label Level

Cetrorelix is a prescription injectable peptide that acts as an antagonist at gonadotropin-releasing hormone (GnRH) receptors. Unlike GnRH agonists, which first stimulate and then desensitize the pituitary, antagonists block the receptor directly and lower luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release without an initial flare. A 2023 review in F&S Reports described cetrorelix in reproductive medicine and its role in suppressing premature LH surges during controlled ovarian stimulation (PMID 37223762). A 2002 French-language review discussed the relationship between LH and GnRH antagonists in stimulated cycles (PMID 11981488).

The approved indication, at label level, is the inhibition of premature LH surges in women undergoing controlled ovarian stimulation. Any other application discussed in the literature, including oncology and gynecologic conditions outside that indication, is investigational. A 2005 French-language review in Annales d'Urologie surveyed GnRH antagonists and their place in hormone-dependent disease (PMID 16302712), and a 2000 German-language article discussed oncology drug development including GnRH-directed compounds (PMID 11105239). Those discussions describe research directions, not approved uses. Whether cetrorelix is appropriate in any individual situation is a question for a prescribing clinician.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine, symptom or treatment decision. Nothing here is a dosing instruction, an administration instruction or a safety verdict.

Boxed Warning Status

United States product labeling for cetrorelix acetate for injection does not carry a boxed warning. The absence of a boxed warning is a regulatory fact about the label and says nothing about whether any particular person will experience an adverse reaction. The warnings and precautions sections of the labeling still describe reactions that prescribers are directed to consider, and those are summarized below.

Serious Adverse Reactions and Label Warnings: What Studies Report

Hypersensitivity and anaphylactoid reactions

Labeling for cetrorelix describes hypersensitivity reactions, including anaphylactoid reactions, among the serious events reported with use. Labeling also notes that severe hypersensitivity has been reported after a first administration in some cases. Cetrorelix is a peptide, and labeling identifies known hypersensitivity to the active substance, to extrinsic peptide hormones or to mannitol as contraindications. Signs described in labeling include rash, pruritus, swelling and, in rare cases, systemic reactions. A longitudinal tolerability study in assisted reproduction populations assessed how patients experienced the drugs used in these cycles and recorded tolerability outcomes (PMID 22612224).

Ovarian hyperstimulation syndrome (OHSS)

OHSS is a recognized complication of controlled ovarian stimulation itself, and labeling for cetrorelix addresses it within the context of the stimulation protocol rather than as a direct drug effect. A 2023 systematic review and network meta-analysis in Human Reproduction Update compared GnRH antagonist protocols for ovarian stimulation during assisted reproductive technology treatment and examined outcomes across protocol variants (PMID 36594696). A 2010 study in Reproductive BioMedicine Online examined cycles triggered with a GnRH agonist and explored low-dose human chorionic gonadotropin for luteal support, a strategy studied in antagonist-based protocols (PMID 20113955). Monitoring for OHSS during stimulation is a clinical matter handled by the treating team.

Pregnancy and fetal considerations

Labeling notes that cetrorelix is not indicated in pregnancy and describes reproductive toxicity findings from animal studies in the relevant sections. Because the drug is used in the period before oocyte retrieval, labeling directs attention to the exclusion of pregnancy before administration. Any question about timing relative to conception is directed to the prescribing clinician.

Common Adverse Reactions: What Studies Report

The adverse reactions most commonly listed in cetrorelix labeling from controlled ovarian stimulation trials fall into a small number of categories. The table below groups reactions by body system as they appear in labeling and in published trial reports. Frequencies reported in labeling derive from clinical trials in women undergoing controlled ovarian stimulation, a population that is also receiving gonadotropins, so attribution of any single symptom to cetrorelix alone is difficult.

Injection site reactions

Site reactions are the most frequently listed category in labeling and are generally described as mild and transient, resolving without intervention in most reported cases. A longitudinal study in Systems Biology in Reproductive Medicine examined drug tolerability across assisted reproduction techniques and tracked how patients reported the burden of injectable regimens (PMID 22612224). That kind of patient-reported tolerability data complements label frequency tables, because labeling counts events while tolerability studies capture how bothersome they were.

Nausea and headache

Nausea and headache appear in labeling among reactions reported in controlled ovarian stimulation trials. Both symptoms are also common background events in stimulated cycles, where gonadotropins, trigger medications and the procedure itself contribute. The 2023 reproductive medicine review of cetrorelix discussed the drug's profile within these multi-drug protocols (PMID 37223762).

Comparative Data Across GnRH Antagonists

Several published comparisons placed cetrorelix alongside other antagonists. A 2009 study in Clinical and Experimental Obstetrics & Gynecology compared cetrorelix with ganirelix for pregnancy outcome using minimal gonadotropin stimulation in women with elevated day 3 serum FSH levels (PMID 19860353). A 2023 network meta-analysis in Human Reproduction Update addressed which antagonist protocol configuration performed best across assisted reproductive technology cycles (PMID 36594696). Researchers in a 2022 pharmacology paper characterized linzagolix, an orally active non-peptide GnRH receptor antagonist, and positioned it against injectable peptide antagonists in receptor pharmacology terms (PMID 35690889). These comparisons concern efficacy and pharmacology more than head-to-head safety, and none of them replaces the label as the source of adverse reaction frequencies.

Class-level considerations in gynecologic research

A 2025 meta-analysis in Archives of Gynecology and Obstetrics assessed the efficacy of GnRH antagonists in the treatment of uterine fibroids (PMID 39821450). Hypoestrogenic effects, such as vasomotor symptoms and effects on bone mineral density, are the class-level concerns discussed in the fibroid and endometriosis literature where antagonists are given for extended periods. Cetrorelix as approved is used for a short interval within a stimulation cycle rather than for months, so that exposure pattern differs substantially from the long-term antagonist studies. Extended use of cetrorelix for gynecologic indications is investigational.

Preclinical and Animal Reports

Several animal studies examined cetrorelix in contexts unrelated to its approved indication. A 2018 study in the Asian Pacific Journal of Cancer Prevention examined adverse effects of vincristine chemotherapy on cell changes in seminiferous tubules in mice and evaluated inhibitory effects of the GnRH antagonist cetrorelix in that model (PMID 29580040). A 2022 study in Biomedicine & Pharmacotherapy reported that ephedra herb reduced adriamycin-induced testicular toxicity by upregulating the gonadotropin-releasing hormone signalling pathway, a model that also probed GnRH pathway manipulation (PMID 35658231). Animal work of this kind describes mechanism in a model organism; it does not establish human adverse event rates and does not describe approved use.

How to Read Adverse Event Numbers

Frequencies in labeling come from the clinical trial program that supported approval, in a defined population under protocol conditions. Numbers from a single trial will not match post-marketing reporting, where events are reported voluntarily and denominators are unknown. Several points shape interpretation:

• Co-administered drugs. Cetrorelix is given inside a protocol that also includes gonadotropins and a trigger agent, so symptom attribution is shared. The 2023 review of cetrorelix in reproductive medicine discussed this protocol context (PMID 37223762).
• Population. Trial populations were women undergoing controlled ovarian stimulation. The 2009 comparison enrolled women with elevated day 3 serum FSH levels, a narrower group (PMID 19860353).
• Endpoint choice. The 2023 network meta-analysis focused on protocol performance in assisted reproductive technology rather than on cataloguing adverse events (PMID 36594696).
• Species. Findings in mice, as in the 2018 seminiferous tubule study, do not transfer to human frequency estimates (PMID 29580040).

Where Questions Belong

Symptoms experienced during or after a prescribed course, questions about whether a reaction is expected, questions about contraindications, interactions or pregnancy status, and any question about dosing or administration belong with the prescribing clinician and the pharmacist who dispensed the product. The current FDA-approved prescribing information is the authoritative source for warnings, contraindications and adverse reaction frequencies, and it is updated over time. Summaries such as this one lag behind the label.

No page on this site tells a reader what to do with a medicine. The material above describes what product labeling states and what published research reported, so that a conversation with a clinician can be better informed.

References

• Cetrorelix in reproductive medicine (F&S Reports, 2023)
• What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis (Human Reproduction Update, 2023)
• Drug tolerability in assisted reproduction techniques: a longitudinal study (Systems Biology in Reproductive Medicine, 2012)
• The effect of cetrorelix vs. ganirelix on pregnancy outcome using minimal gonadotropin stimulation in women with elevated day 3 serum follicle stimulating hormone levels (Clinical and Experimental Obstetrics & Gynecology, 2009)
• Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support (Reproductive BioMedicine Online, 2010)
• Efficacy of GnRH antagonists in the treatment of uterine fibroids: a meta-analysis (Archives of Gynecology and Obstetrics, 2025)
• Pharmacological characterization of linzagolix, a novel, orally active, non-peptide antagonist of gonadotropin-releasing hormone receptors (Clinical and Experimental Pharmacology & Physiology, 2022)
• Adverse Effects of Vincristine Chemotherapy on Cell Changes in Seminiferous Tubules and Cetrorelix GnRH Antagonist Inhibitory Effects in Mice (Asian Pacific Journal of Cancer Prevention, 2018)
• Ephedra herb reduces adriamycin-induced testicular toxicity by upregulating the gonadotropin-releasing hormone signalling pathway (Biomedicine & Pharmacotherapy, 2022)
• [GnRH antagonists: present and future] (Annales d'Urologie, 2005)
• [LH and GnRH antagonists] (Journal de Gynecologie, Obstetrique et Biologie de la Reproduction, 2002)
• Arzneimittelentwicklung in der Onkologie. Status und Ausblick unter besonderer Berucksichtigung des Standortes Deutschland (Arzneimittel-Forschung, 2000)